💥FOIA documents show FDA examined reports of persistent sexual dysfunction tied to antidepressants — but declined stronger warnings
Critics say the FDA set too high an evidentiary bar before deciding against stronger warnings about persistent sexual dysfunction linked to antidepressants.
Link 👇👇
@abcsoka @PSSDNetwork @MikhailaFuller @unhealthytruth @benzosarebad @woodymatters
@jeffreytucker @Mangan150 @newstart_2024
In 2018, a citizen petition urged the FDA to update labels for SSRIs/SNRIs, warning that sexual dysfunction could continue long after discontinuation.
Years later, petitioners sued @US_FDA for failing to respond.
@DrDavidHealy @abcsoka @PssdWarrior @PSSDNetwork
blog.maryannedemasi.com/p/fda-sued-for…
In light of new FOIA docs, A/Prof Csoka said he was not aware the FDA had reached any internal decision.
“If the FDA concluded that the evidence did not justify a label change, it should have said so openly, explained its reasoning, addressed the evidence submitted, and clarified what additional evidence would be needed,” said @abcsoka.
🗒️Notably, other drug regulators have taken a different approach.
Authorities in Europe, Canada and Australia have updated product information to acknowledge that sexual dysfunction can, in some cases, persist after discontinuation of antidepressant treatment.
@EMA_News @canadianhealthy @TGAgovau
A/Prof Csoka said the failure of the @US_FDA to respond, raises broader concerns about the agency's accountability.
Full story: blog.maryannedemasi.com/p/fda-examined…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.